CGTX — COGNITION THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1455365 ·
Last close
$0.63
Market Cap
$59.90M
52W High
$1.81
52W Low
$0.55
ADV30
537,332
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,411,000 | -4,145,000 | 34,803,000 | 30,758,000 | 5,526,000 |
| Jun 2026 | 0 | — | -4,220,000 | -3,932,000 | 38,896,000 | 34,012,000 | 5,872,000 |
| Mar 2026 | 0 | — | -4,838,000 | -4,570,000 | 36,140,000 | 31,130,000 | 6,229,000 |
| Dec 2025 | 0 | — | -3,672,000 | -3,343,000 | 48,390,000 | 36,810,000 | 14,119,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,291,000
Investing CF
$-11,000
Financing CF
$6,954,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.19
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-211,294,000
Inventory
—
Receivables
$2,503,000
ST Investments
—
EBIT TTM
$-15,976,000
Pretax Income TTM
$-15,990,000
Interest Exp TTM
$14,000
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,393,000 | -23,487,000 | 48,390,000 | 14,119,000 | 34,271,000 | -24,588,000 |
| Dec 2024 | 0 | -34,417,000 | -33,971,000 | 30,234,000 | 11,484,000 | 18,750,000 | -28,474,000 |
| Dec 2023 | 0 | -25,919,000 | -25,788,000 | 35,163,000 | 10,689,000 | 24,474,000 | -16,018,000 |
| Dec 2022 | 0 | -21,334,000 | -21,397,000 | 50,425,000 | 10,176,000 | 40,249,000 | -18,533,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-16,775,000
OpCashFlow TTM
—
Assets (Latest)
$38,896,000
Forward EPS
$-0.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PMCB | PharmaCyte Biotech, Inc. | $58.19M | $5.42 | — |
| OKYO | OKYO Pharma Ltd | $57.99M | $1.11 | — |
| NMRA | Neumora Therapeutics, Inc. | $62.85M | $0.33 | — |
| VISK | Viskase Holdings, Inc. | $63.49M | $4.43 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $63.91M | $4.59 | — |
News headlines (Yahoo Finance, 1h cache)
Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
2026-11-17 11:00 · Yahoo
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
2026-11-10 19:43 · Yahoo
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
2026-11-09 12:30 · Yahoo
Cognition Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 23:25 · Yahoo
Cognition Tx (CGTX) Q3 2026 Earnings Call Transcript
2026-11-05 20:45 · Yahoo
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
2026-11-05 11:00 · Yahoo
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
2026-11-02 12:30 · Yahoo
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
2026-10-22 10:00 · Yahoo
Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development
2026-10-13 10:59 · Yahoo
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
2026-10-13 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.